Relay Therapeutics (NASDAQ: RLAY) stock dropped 36% yesterday on news about the testing of a drug candidate. As we can imagine from that reaction the drug isn't quite working out as hoped. But this is an example of the grand bargain made in backing any research or clinical state pharma company. Sure, the rewards to something that actually makes it through to market are large and worth it. But there are a number of potential failure points along the way Failing at any of them usually - not always but usually - meaning a total loss on what has been spent so far.
This is simply how this area of pharma works. Research is concentrated in small independent companies. These live off shareholder capital. Some is raised, work done, the candidate passes the first test, more is raised and so on. As and when FDA approval is reached then either the company or the drug is sold on or licenced to one of the majors. Failure at any point wipes out the capital that has been invested so far. It might be, for a one drug company, the whole company that then goes. Or, as here, it might be only that portion of the development process which is represented by the one of many candidates.

Relay Therapeutics share price from NASDAQ
The specific problem here at Relay is the results on RLY-2608. The initial release paints a hopeful picture. The way that's written we'd think things were going swimmingly in fact. Clearly, given the stock price response, that wasn't the correct reading of the data.
The bigger lesson for us here is that pharm companies are like Tolstoy's families- each can be unhappy in its own way. There are many potential failure points along the path to full approval. It has to be non-toxic to start with, then it has to actually work (what is being tested here) then it needs to have few to no side effects and so on. A failure at any one point along this process wipes out the previous investment. That's why investing in clinical stage pharma is such a risky business - there are so many different ways it can all go wrong.



